Clinical Trial

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

Study acronym: TIGOS-LS
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants. The main goals of this study are to: * Evaluate the efficacy of BMS-986489 vs durvalumab * Evaluate the safety profile of BMS-986489
Protocol Amendment History 1 change
notable Trial sites expanded: 30 -> 33 locations 2026-04-23
Trial Details
NCT Number NCT06773910
Lead Sponsor SCRI Development Innovations, LLC
Collaborators: Bristol-Myers Squibb
Conditions Limited Stage Small Cell Lung Cancer
Enrollment 250 participants
Start Date 2025-03-11
Primary Completion 2032-05 (estimated)
Study Completion 2032-09 (estimated)
Updated on ClinicalTrials.gov 2026-04-22